POSTPRANDIAL LIPEMIA, INFLAMMATION, AND VASCULAR FUNCTION IN DIABETES MODULATED BY SGLT2 INHIBITION - PLEIADES

Franciscus Gasthuis0 个研究点开始时间: 2016年11月8日最近更新: 2017年5月8日

适应症

试验速览

暂无简介。

•- Age of 18 years of older;
•- Diabetes mellitus type 2 on intensive insulin treatment (three times short acting and once daily long acting) (unchanged for > 10 weeks prior to consent)
•- Stable glucose regulation last 6 months (HbA1c > 6.5% - < 9.0%)
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 20
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•- Current smoking
•- Impaired renal function (MDRD <60 ml/min/1.73 m2)
•- Recent use of SGLT-2 inhibitor (past 6 months)
•- Recent cardiovascular event (past 6 months) (myocardial infarction, coronary artery bypass grafting, stroke)
•- Severe hyperglycemic events in the past 6 months (hyperglycemia >20 mmol/l requiring hospital admittance)

发起方

Franciscus Gasthuis